The Prevalence Survey of ALDH Gene Family in Patients With Peripheral Arterial Occlusive Disease or Acute Coronary Syndrome

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age20+
SponsorChimei Medical Center

About this trial

Aldehyde dehydrogenase 2 (ALDH2) is an important enzyme protecting human from the accumulation of aldehyde, the main metabolites of alcohol. The deficiency of ALDH2 gene results in flush and hang over post drinking and most importantly it has been found associated with the incidence of cancer and post myocardial infarction (MI) heart failure. In the previous studies, ALDH2 decreased the ischemic territory post infarction and using a large scaled interaction of genetic variants and ALDH2 as an instrument, the threats of alcohol consumption on Asians' cardiovascular health was underscored. Furthermore, in a meta-analysis reviewing 12 case-control studies also indicated an increase of 48% risks in patients with ALDH2 deficiency. Notably, the genetic deficiency is most prevalent in Asians. In Taiwan one of every two individuals may be the victim and the high prevalence is counted as the top of the world. However, a large scaled prospective study focusing on the prevalence of ALDH2 deficiency in patients with peripheral artery occlusive disease (PAOD) or acute coronary syndrome (ACS)remains lacking.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age≧20 y/o

Using ankle-brachial index (ABI)< 0.9, angiography, vascular duplex, CAT scan or cardiologists'impression to confirm the diagnosis of PAOD

Clinical presentation of claudication

diagnosis of ACS

Disqualifiers

If the patient refuses to be included in this study

Trial population

Diagnosed as peripheral arterial obstruction or acute coronary syndrome.

Trial design

Design model

Case-only

Time perspective

Prospective

Treatments tested in this trial

  • Observational research

    Other intervention

    Observational research

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

The incidence of MALE(major adverse limb events) in peripheral arterial disease and acute coronary disease.

Time frame
2 years

Secondary outcomes

1

The incidence of MACCE(major adverse cardiac and cerebrovascular events) in peripheral arterial disease and acute coronary disease.

Time frame
2 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.